The U.S. Centers for Disease Control and Prevention (CDC) activated its highest Level 1 response on June 26 to combat an Ebola outbreak in the Democratic Republic of Congo (DRC). While the CDC maintains the risk to the United States remains low, officials are deploying experimental MBP134 treatments and 2,500 diagnostic tests to contain the Bundibugyo strain.
Why did the CDC activate a Level 1 response?
The CDC implemented a Level 1 response on June 26, the same highest-level protocol used during the worst-ever Ebola epidemic in 2014. A CDC official described this designation as an “internal cue” to signal that the current outbreak is a top priority for the agency.
This heightened status allows the agency to mobilize staffing and additional resources with maximum efficiency. Satish Pillai, who is leading the Ebola response at the CDC, stated that the current assessment indicates the risk to the United States continues to remain low.
The decision follows a rapid increase in infections within the region. In just over one month, the epidemic in the DRC has resulted in 1,115 confirmed infections and 304 deaths.
How does this outbreak compare to the 2014 epidemic?
Health officials are monitoring the situation closely to prevent a repeat of the 2014-2016 West Africa crisis. If the current outbreak is not contained quickly, US health officials warned it could reach or exceed the scale of that previous epidemic.
The scale of these two events differs significantly in total mortality:
- Current Outbreak: 304 deaths in the DRC and 20 confirmed cases in Uganda (including two deaths in Kampala since May 15).
- 2014-2016 Epidemic: More than 11,000 deaths across West Africa, according to the World Health Organization (WHO).
The 2014 outbreak originated in Guinea and spread through multiple nations, creating a global health emergency. The current situation is being managed with more immediate experimental interventions to prevent a similar trajectory.
The Bundibugyo strain of Ebola is distinct from other strains. Because it is a specific variant, standard vaccines used for other Ebola types may not be effective against it.
What treatments are being used for the Bundibugyo strain?
Because no approved vaccines or treatments currently exist for the Bundibugyo strain, medical authorities are relying on experimental options. On June 26, US health officials announced the shipment of an experimental treatment known as MBP134 to the DRC and Uganda.
To accelerate medical knowledge, additional doses of MBP134 are being sent to the University of Oxford in Britain for clinical trials. This move aims to gather critical data on the treatment’s efficacy against this specific strain.
Diagnostic capabilities are also being bolstered. Washington is prepared to send 2,500 tests designed to screen deceased victims. These tests allow scientists to determine exactly which Ebola strains are present in a population, which is essential for tailoring the medical response.
Frequently Asked Questions
According to Satish Pillai of the CDC, the risk to the United States currently remains low.
MBP134 is an experimental treatment being deployed to the DRC and Uganda because no approved treatments exist for the Bundibugyo strain.
A Level 1 response is the highest level of response activated by the CDC, used to prioritize resources and staffing during major outbreaks.
Stay informed on global health developments. Please share this article or subscribe to our newsletter for the latest updates on international health security.
